GLDM News & Analysis
2 articles
Market Mood
Galderma (GLDM) Faces FDA Setback for Botox Rival Drug
Galderma's stock dropped following the FDA's second setback regarding its rival to Botox. The company has been working on a new injectable treatment aiming to compete in the aesthetics market. The setbacks from the FDA could delay the product launch, impacting anticipated revenue streams. This event raises concerns about regulatory hurdles and market positioning for Galderma (GLDM).
Read More: Galderma (GLDM) Faces FDA Setback for Botox Rival Drug
Gold ETF GLD vs GLDM: Key Metrics and Performance Comparison
Gold prices surged from $2,000 per ounce in early 2024 to over $5,500 in early 2026, driven by central bank buying, safe haven demand, and inflation. The SPDR Gold Shares ETF (GLD) holds over $163 billion in assets but has a higher expense ratio of 0.40%, while the SPDR Gold MiniShares Trust ETF (GLDM) has $32 billion in assets and a lower expense ratio of 0.10%. Over the past five years, GLDM has averaged a 22.1% annual return, compared to GLD's 21.8%, highlighting the benefit of lower costs. The ongoing demand for gold presents investment opportunities for both retail and institutional traders.
Read More: Gold ETF GLD vs GLDM: Key Metrics and Performance Comparison